Innovent Medical Solutions Ltd.
This article was originally published in Start Up
Executive Summary
Ventilator associated pneumonia (VAP), the second most common infection in the ICU, is caused when infected secretions that accumulate in and around the endotracheal tube leak into the lungs. Innovent Medical Solutions Ltd. intends to reduce both the incidence and the cost of treating VAP with noninvasive technology that mimics nature's own method for clearing airways: the cough. T In addition to decreasing the number of VAP cases by 50%, the company thinks its technology will also facilitate more use of noninvasive facemask ventilation, leading to an improvement in the quality of life for ICU patients.